Search

TG Therapeutics Inc

Gesloten

SectorGezondheidszorg

48.74 2.01

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

47.16

Max

48.91

Belangrijke statistieken

By Trading Economics

Inkomsten

7.8M

28M

Verkoop

35M

240M

K/W

Sectorgemiddelde

18.207

57.002

EPS

0.05

Winstmarge

11.466

Werknemers

399

EBITDA

-6.4M

22M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+35.88% upside

Dividenden

By Acuity

Volgende Winsten

2 nov 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

458M

7.5B

Vorige openingsprijs

46.73

Vorige sluitingsprijs

48.74

Nieuwssentiment

By Acuity

6%

94%

7 / 340 Rangschikking in Healthcare

TG Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

14 aug 2026, 21:01 UTC

TG Therapeutics Inc shares are lower in after-market trading amid broader market weakness. Disappointing U.S. retail sales data may be impacting investor sentiment.

13 aug 2026, 20:02 UTC

Social Media

TG Therapeutics Inc shares declined during Thursday's session, influenced by social media sentiment and prior bearish commentary from Bank of America.

10 aug 2026, 19:16 UTC

TG Therapeutics Inc shares are lower today amid a broader market decline, with U.S. stock futures dropping following a surprising labor market report.

7 aug 2026, 23:16 UTC

TG Therapeutics Inc shares are lower in after-market trading. No specific news was identified to explain the movement, which may reflect broader market sentiment.

6 aug 2026, 20:03 UTC

News

TG Therapeutics is lower today, impacted by declines in the Biotechnology sector. The company reported higher revenue but noted a decrease in net income and EPS.

5 aug 2026, 19:56 UTC

Social Media

TG Therapeutics is higher as analysts project GAAP net income could exceed $350 million in 2027, driven by revenue growth and pipeline developments.

4 aug 2026, 23:56 UTC

TG Therapeutics Inc. shares are roughly flat in after-market trading. The price remains below its 20-day moving average, indicating ongoing weakness.

3 aug 2026, 23:06 UTC

Social Media

TG Therapeutics Inc. shares are higher in after-market trading following Q2 revenues of $236 million and ongoing positive sentiment from clinical trials.

31 jul 2026, 23:16 UTC

No specific news was identified for TG Therapeutics Inc. After-market trading remains routine, with the stock showing little change in value.

30 jul 2026, 23:56 UTC

TG Therapeutics Inc shares are lower in after-market hours, with no specific news identified for the decline amid broader market uncertainty over interest rates.

29 jul 2026, 15:52 UTC

Social Media
News

TG Therapeutics shares are lower amid negative sentiment following the announcement of a conference call to discuss second quarter results and future outlook.

28 jul 2026, 19:56 UTC

TG Therapeutics shares are lower today amid broader market declines and a significant drop in the Nikkei 225 Index, reflecting negative sentiment.

27 jul 2026, 19:07 UTC

Social Media

B. Riley raised its price target for TG Therapeutics to $86, citing strong demand for Briumvi and anticipated revenue growth. Shares are trading roughly flat.

24 jul 2026, 23:21 UTC

TG Therapeutics Inc shares are lower in after-market hours, reaching a significant decline and hitting the lowest point of the day. No specific news was identified.

23 jul 2026, 23:22 UTC

TG Therapeutics traded roughly flat in after-market hours, with minimal change since Thursday's close, oscillating within its one-month trading range.

22 jul 2026, 23:31 UTC

TG Therapeutics Inc shares declined in after-market trading, reflecting a shift toward the lower end of its one-month trading range amid broader market pressures.

21 jul 2026, 22:21 UTC

TG Therapeutics shares are higher in after-market trading, tracking broader market gains following positive earnings from General Motors and 3M.

20 jul 2026, 23:22 UTC

TG Therapeutics shares are higher in after-market trading, recovering from a prior dip despite broader market pressures and four consecutive sessions of declines.

Peer Vergelijking

Prijswijziging

TG Therapeutics Inc Prognose

Koersdoel

By TipRanks

35.88% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 65.14 USD  35.88%

Hoogste 86 USD

Laagste 21 USD

Gebaseerd op 7 Wall Street-analisten die 12-maands prijsdoelen bieden voor TG Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

7 ratings

5

Buy

1

Hold

1

Sell

Sentiment

By Acuity

7 / 340 Rangschikking in Gezondheidszorg

Nieuwssentiment

Zeer Sterk Bearish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Boven gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over TG Therapeutics Inc

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.
help-icon Live chat